Zucara Therapeutics secures funding for diabetes drug

Veronica Silva
April 17, 2018

Life sciences firm Zucara Therapeutics Inc. has secured non-dilutive funding of US$3.9 million for the pre-clinical advancement of its lead drug candidate for diabetes, ZT-01. Zucara’s partner, The Leona M. and Harry B. Helmsley Charitable Trust, will provide the funds in the form of a loan under a program-related investment (PRI). ZT-01 is focused on the prevention of hypoglycemia or dangerously low blood glucose levels, which may lead to unconsciousness or death, in patients with Type 1 diabetes (T1D) and other types of insulin-dependent diabetes. For its lead drug to be on schedule for Phase I clinical trials in 2019, Zucara is pushing forward with GLP toxicology, GMP manufacturing and other investigational new drug/clinical trial application enabling activities. Zucara chief scientific officer Richard Liggins, who has helped several similar-stage therapeutics reach clinical trials, will lead the preclinical development work. To build and advance its products, Zucara is working closely with the Centre for Drug Research and Development (CDRD).


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events











Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.